ClinicalTrials.gg
Status unknownNCT01517633Updated Jan 25, 2012

Study of a Diagnostic Device for Identifying Between Amniotic Fluid to Urine

A Phase 2/3 interventional study of BirthSign in Amniotic Fluid Leakage, sponsored by Hadassah Medical Organization. Status unknown at 1 site in Israel. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-01-25.

Sponsored by Hadassah Medical Organization · Phase 2/3, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Jan 2012), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Phase 2/3
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to compare the reliability and validity of a new device with standard methods for diagnosing between amniotic fluid leakage due to premature rupture of the membranes (PROM) and urine.

Read the detailed description

Pregnant women sensing wetness and arriving to the delivery room with suspect PROM will use a self-testing device to test whether the wetness is caused by amniotic fluid leakage or urinary incontinence. Clinical evaluation will be performed to all pregnant women using standard clinical tests. The results of the standard clinical tests will be compared to the women's reading of the self-testing device results. Sensitivity and specificity of the device evaluation will be calculated.

02

Conditions studied

  • Amniotic Fluid Leakage

Keywords

  • Amniotic fluid leakage
  • Urinary incontinence
03

In context

Urinary Incontinence

1,375 studies on the registry are indexed under Urinary Incontinence; 224 are open to participants now.

This study's planned enrollment of 100 is above the median of 66 across 1,021 interventional studies indexed under Urinary Incontinence.

Browse Urinary Incontinence studies →

Lead sponsor

Hadassah Medical Organization is the lead sponsor of 674 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pregnant women age 18 years and older attending delivery room.
  2. Stage of gestation: pregnancy between 16 and 42 weeks of gestation.
  3. Able and willing to read and sign an informed consent document.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study if any of the following will be present:

  1. Prior use of any amniotic fluid detection test.
  2. Use of vaginal douching apparatus (such as a vaginal bulb syringe) or vaginal products such as creams or gels within the past 24 hours.
  3. Vaginal bleeding or spotting or excess abnormal vaginal discharge within the past 24 hours.
  4. Sexual intercourse within the past 24 hours.
  5. Confirmed diagnosis of any vaginal infection within the past 7 days.
  6. Use of vaginal products or antibiotic treatments that reduce bacterial population or use of medications such as tamoxifen that reduce estrogen levels or antihistamines that dry mucous membranes within the past 7 days..
  7. Patients unable or unwilling to participate.
  8. Patients in active labor (or with regular contractions).
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    A device for identifying between amniotic fluid and urine

    Device: BirthSign

Interventions

  • DeviceBirthSign

    When leakage from the vagina occurs, the woman will wet the indicator lines of the device with the body fluids.

06

What researchers measure

Primary outcomes

  1. Presence / absence of stains comparing to a known color index printed on the product

    Presence / absence of a blue-green stain and / or brown-red stain as yielded by the device and observed by the woman.

    Time frame: 12 hours

Secondary outcomes

  1. Presence / absence of stains comparing to a known color index printed on the product

    Presence / absence of a blue-green stain and / or brown-red stain as yielded by the device and observed by the clinician and a measurement of patient comfort while using the device, reading the results and clarity of instructions.

    Time frame: 12 hours

07

Study locations

1 site
  • Hadassah Medical Organization
    Jerusalem, 91120, Israel
08

References and documents

Publications

  • El-Messidi A, Cameron A. Diagnosis of premature rupture of membranes: inspiration from the past and insights for the future. J Obstet Gynaecol Can. 2010 Jun;32(6):561-569. doi: 10.1016/S1701-2163(16)34525-X. PubMed 20569537 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012 and a primary completion of Jan 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2012
First posted
Jan 25, 2012
Start
Jan 2012
Primary completionEst.
Jan 2013
Last update
Jan 25, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01517633
Responsible party
Sponsor
First posted
Jan 25, 2012
Start date
Jan 2012
Primary completion
Jan 2013 (estimated)
Last update
Jan 25, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion